{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:25:33Z","timestamp":1778883933665,"version":"3.51.4"},"reference-count":38,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The achievements in the treatment of metastatic colorectal cancer during recent years are based on a better understanding of the disease and individualized regimen planning. In adjuvant treatment, the highly important IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study has shown that treatment duration can safely be reduced in selected patient populations. In patients with pN1 and pT1-pT3 tumors, 3 months of treatment with 5-fluorouracil and oxaliplatin is comparable with respect to 3-year survival rate to 6 months of treatment. For patients with N2 tumors, 6 months of treatment should stay the standard of care. The limitation of the duration of the adjuvant treatment is significantly reducing the chemotherapy-induced morbidity. New studies will explore the use of immune-checkpoint inhibitors in the adjuvant setting in microsatellite-instable (MSI) tumors. In metastatic disease, next to the required molecular testing for <ns4:italic>RAS<\/ns4:italic> and <ns4:italic>BRAF<\/ns4:italic> mutations, MSI testing is recommended. In the rare group of patients with a MSI tumor, immune-checkpoint inhibition is changing the course of the disease dramatically. Therefore, it is important to identify those patients early. For the <ns4:italic>RAS<\/ns4:italic>-mutant cases, no new and targeted treatment options have been identified yet. An optimal treatment strategy for those patients is urgently needed. <ns4:italic>RAS<\/ns4:italic> wild-type patients with tumors derived from the left side of the colon (splenic flexure to rectum) should be treated in first line with epithelial growth factor receptor (EGFR) antibodies. This selection by a molecular and a clinical marker increased the benefit derived by EGFR antibodies dramatically and defined the most effective treatment option for those patients. New selection criteria based on gene expression, methylation, and other molecular changes are explored and will further influence our therapeutic strategies in the future.<\/ns4:p>","DOI":"10.12688\/f1000research.14604.1","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T03:40:05Z","timestamp":1537760405000},"page":"1528","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Recent advances in understanding colorectal cancer"],"prefix":"10.12688","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-5801","authenticated-orcid":false,"given":"Sebastian","family":"Stintzing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"2392-401","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.","volume":"317","author":"A Venook","year":"2017","journal-title":"JAMA."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1426-34","DOI":"10.1016\/S1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.","volume":"17","author":"S Stintzing","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"3109-16","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.","volume":"27","author":"T Andr\u00e9","year":"2009","journal-title":"J Clin Oncol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"3768-74","DOI":"10.1200\/JCO.2011.36.4539","article-title":"Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.","volume":"29","author":"G Yothers","year":"2011","journal-title":"J Clin Oncol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1177-88","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.","volume":"378","author":"A Grothey","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"4176-87","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.","volume":"33","author":"T Andr\u00e9","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"211-22","DOI":"10.1056\/NEJMoa1506597","article-title":"CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.","volume":"374","author":"P Dalerba","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-8","article-title":"NCCN Guidelines Colon Cancer Version 1.2017","year":"2016"},{"key":"ref-9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.2018.36.4_suppl.678","article-title":"An assessment of KRAS, NRAS, and BRAF testing prior to 1st line of therapy among mCRC patients treated at community cancer centers in the United States.","volume":"36","author":"A Florea","year":"2018","journal-title":"J Clin Oncol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"773-9","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer.","volume":"36","author":"M Overman","year":"2018","journal-title":"J Clin Oncol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"2509-20","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.","volume":"372","author":"D Le","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"330-7","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer.","volume":"487","year":"2012","journal-title":"Nature."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"1306-15","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.","volume":"16","author":"C Cremolini","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"4032-8","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.","volume":"33","author":"S Kopetz","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1200\/JCO.2017.35.4_suppl.520","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).","volume":"35","author":"S Kopetz","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"104-15","DOI":"10.1158\/1078-0432.CCR-16-0140","article-title":"BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.","volume":"23","author":"D Barras","year":"2017","journal-title":"Clin Cancer Res."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1386-422","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.","volume":"27","author":"E van Cutsem","year":"2016","journal-title":"Ann Oncol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"692-700","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.","volume":"33","author":"E van Cutsem","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1023-34","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.","volume":"369","author":"J Douillard","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1179-90","DOI":"10.1007\/s00384-017-2800-1","article-title":"Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.","volume":"32","author":"F Rivera","year":"2017","journal-title":"Int J Colorectal Dis."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"81-90","DOI":"10.1016\/j.clcc.2014.12.011","article-title":"Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.","volume":"14","author":"M Khattak","year":"2015","journal-title":"Clin Colorectal Cancer."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"11-20","DOI":"10.1016\/j.ejca.2016.07.019","article-title":"A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.","volume":"67","author":"V Heinemann","year":"2016","journal-title":"Eur J Cancer."},{"key":"ref-23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.18_suppl.lba3","article-title":"CALGB\/SWOG 80405: Phase III trial of irinotecan\/5-FU\/leucovorin (FOLFIRI) or oxaliplatin\/5-FU\/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).","volume":"32","author":"A Venook","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.","author":"S Tejpar","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref-25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju427","article-title":"Primary tumor location as a prognostic factor in metastatic colorectal cancer.","volume":"107","author":"F Loupakis","year":"2015","journal-title":"J Natl Cancer Inst."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1713-29","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.","volume":"28","author":"D Arnold","year":"2017","journal-title":"Ann Oncol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"69-80","DOI":"10.1016\/j.ejca.2017.07.016","article-title":"Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.","volume":"84","author":"S Stintzing","year":"2017","journal-title":"Eur J Cancer."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"87-98","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.","volume":"70","author":"J Holch","year":"2017","journal-title":"Eur J Cancer."},{"key":"ref-29","article-title":"NCCN Guidelines Colon Cancer Version 2.2018","year":"2018"},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"44-70","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.","volume":"29","author":"T Yoshino","year":"2018","journal-title":"Ann Oncol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"88-99","DOI":"10.1053\/j.gastro.2014.09.041","article-title":"Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.","volume":"148","author":"F Sinicrope","year":"2015","journal-title":"Gastroenterology."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"847-54","DOI":"10.1136\/gutjnl-2011-300865","article-title":"Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.","volume":"61","author":"M Yamauchi","year":"2012","journal-title":"Gut."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"208-15","DOI":"10.4143\/crt.2014.314","article-title":"p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer.","volume":"48","author":"S Kim","year":"2016","journal-title":"Cancer Res Treat."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2017.35.15_suppl.3503","article-title":"Primary (1\u00b0) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB \/ SWOG 80405 (Alliance).","volume":"35","author":"A Venook","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1350-6","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer.","volume":"21","author":"J Guinney","year":"2015","journal-title":"Nat Med."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1200\/JCO.2017.35.15_suppl.3510","article-title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.","volume":"35","author":"S Stintzing","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1200\/JCO.2017.35.15_suppl.3511","article-title":"Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB\/SWOG 80405 (Alliance).","volume":"35","author":"H Lenz","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"738-46","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.","volume":"17","author":"A Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1528\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1528\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1528\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T15:31:12Z","timestamp":1553873472000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1528\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":38,"URL":"https:\/\/doi.org\/10.12688\/f1000research.14604.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.15893.r38512","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.15893.r38513","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1528\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.15893.r38512, John Zalcberg, School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia, 24 Sep 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1528\/v1#referee-response-38512","order":0,"name":"referee-response-38512","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.15893.r38513, Axel Grothey, West Cancer Clinic, Germantown, Tennessee, USA, 24 Sep 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1528\/v1#referee-response-38513","order":1,"name":"referee-response-38513","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}